Novartis Malaysia and Institut Jantung Negara Jointly Collaborate To Tackle Atherosclerotic Cardiovascular Disease

1st ever scientific partnership in the treatment paradigm of Atherosclerotic Cardiovascular Disease (ASCVD) aiming to help patients improve the management of the disease through better care and transformative therapies

Novartis Malaysia and Institut Jantung Negara Jointly Collaborate To Tackle Atherosclerotic Cardiovascular Disease
Dr. Mayuresh Fegade, Chief Scientific Officer of Novartis Malaysia; Mr. Elwakil Mohamed, Country President of Novartis Malaysia; Datuk Dr. Aizai Azan, Chief Executive Officer of Institut Jantung Negara, and Dr. Hasri Samion, Chief Clinical Officer of IJN formalising the scientific research partnership between IJN and Novartis Malaysia. 

Petaling Jaya, August 1, 2022 Novartis Corporation (Malaysia) Sdn Bhd (Novartis Malaysia) has partnered with Institut Jantung Negara (IJN) on the first-ever scientific partnership to help patients improve disease management of ASCVD through better care and transformative therapies.

ASCVD diseases such as coronary heart disease (CHD), stroke, and peripheral arterial disease (PAD) are caused by the buildup of high cholesterol level hardening and narrowing arteries.

In a first of its kind partnership, the collaboration between Novartis Malaysia and IJN encompasses one of the most comprehensive collaboration featuring three key areas of focus which includes:

  • Research collaboration aimed to generate data on ASCVD in Malaysia and measure outcomes of ASCVD patients.
  • The establishment of a state-of-the-art multi-disciplinary Cardiovascular Risk Reduction Clinic (CRRC) to optimize ASCVD care.
  • Establishing IJN as an internationally recognized training center of excellence in ASCVD care.
Group photo of Dr. Mayuresh Fegade, Chief Scientific Officer of Novartis Malaysia; Dato’ Dr. Suhaini Kadiman, Director of Clinical Research of IJN; Mr. Elwakil Mohamed, Country President of Novartis Malaysia; Datuk Dr. Aizai Azan, Chief Executive Officer of IJN; Dr. Hasri Samion, Chief Clinical Officer of IJN and Dato’ Sri’ Dr. Azhari Rosman, Sr. Consultant Cardiologist of IJN, the team that realized the scientific partnership.

Cardiovascular disease

Mohamed El-Wakil, Country President, Novartis Malaysia, said: “Novartis recognizes that ASCVD is an undeniable global public health issue and the world’s number one killer. The World Health Organization (WHO) estimates that over 15 million people die from ASCVD every year, accounting for 85% of cardiovascular death. While in Malaysia the National Health and Morbidity Survey 2019, reported that non-communicable diseases (NCD) accounted for 71% of premature deaths in Malaysia. Of key concern within NCDs is ASCVD which contributes to 54% of all NCD deaths.”

“Staying true to our purpose of reimagining medicines to improve and extend people’s lives, we learned about our patients’ journey and develop solutions to meet those gaps and needs in cardiovascular care.”

“This pioneering collaboration between Novartis Malaysia and IJN is crucial as it can be a potential game-changer within the ASCVD treatment paradigm. It brings together the expertise and impeccable standards of care by the nation’s premier cardiovascular specialist institution, IJN, together with the comprehensive experience of Novartis in the area of cardiovascular.

The partnership has already achieved its first milestone with the Cardiovascular Risk Reduction Clinic (CRRC) to optimize ASCVD care. Dato’ Sri Dr. Azhari Rosman; Nurse Choong Shiau Yin, Diabetes Educator of IJN; Dr. Thum Chan Ho, Clinical Fellow, Department of Cardiology of IJN, together with Mr. Elwakil Mohamed, Country President of Novartis Malaysia and Dr. Mayuresh Fegade, Chief Scientific Officer of Novartis Malaysia visited the CRRC.

The scientific partnership also represents a significant milestone in the long-standing collaboration between Novartis Malaysia and IJN. Past partnerships with IJN include the IJN-Acute Decompensated Heart Failure (ADHF) Registry which was published internationally and the IJN Heart Failure Clinic.

Novartis’s AXON Technology wins Medical Technology - Pharmaceuticals award
AXON is Malaysia’s first machine learning-powered application developed by Novartis Malaysia that predicts cardiac events for heart disease patients after balloon angioplasty.

NCD

Datuk Dr. Aizai Azan Abdul Rahim, Chief Executive Officer of Institut Jantung Negara, said: “This collaboration is indeed timely as the prevalence of ASCVD is increasing. In addition, the Ministry of Health has just revealed the National Strategic Plan for Non-Communicable Disease (NCD) 2016-2025, aiming to reduce NCD deaths from 20% to 15% by 2025i. We are looking forward to our collaboration with Novartis Malaysia to achieve our goal “What Good Looks Like” in ASCVD care.”

To date, the partnership has already achieved its first milestone with the launch of the Cardiovascular Risk Reduction Clinic (CRRC). The CRRC which is hosted every Monday in IJN, will provide effective and aggressive lipid and CV risk management for patients with CVD and primary lipid disorders in optimizing ASCVD care. It is driven by a systematic management protocol with well pre-defined inclusion criteria and checklist, led by a trained multi-disciplinary team (clinicians, nurses, dieticians, physiotherapists, and pharmacists).